Dipyridamole-Dobutamine Stress Echocardiography for the Detection of Myocardial Ischemia in Patients with Hypertension

Purpose: To assess the value of dipyridamole-dobutamine stress echocardiography test (Dip-Dob SET) in detecting myocardial ischemia in hypertensive patients with chest pain and to compare it with the results of the dipyridamole-atropine stress echocardiography test (Dip-Atro SET). Patients and Methods: 127 consecutive hypertensives with chest pain (82 male, mean age 54.5 ′ 7.9 years) and nondiagnostic exercise stress test were evaluated. Patients were randomly assigned to receive dobutamine 5-40 μg/kg/min (Dip-Dob group, 55 patients) or atropine 0.25 mg in four divided doses up to 1 mg (Dip-Atro group, 72 patients), if high Dip SET was negative (Dip up to 0.84 mg/kg over 10 min). 84 patients underwent coronary angiography (42 in the Dip-Atro and 42 in the Dip-Dob group). Results: 76 tests were positive for new dyssynergy (16 segment/ 4-grade model of wall motion analysis), 39 in the Dip-Atro and 37 in the Dip-Dob group, 42 were negative, and nine were stopped due to non-life-threatening side effects, four in the Dip-Atro and five in the Dip-Dob group. Delta wall motion score index (WMSI) was significantly higher in the Dip-Dob than the Dip-Atro group (0.34 ′ 0.3 vs. 0.21 ′ 0.4; p 0.05). Sensitivity, specificity, diagnostic accuracy, positive predictive value, and negative predictive value were 92.9%, 78.6%, 88.1%, 89.7%, and 84.6% versus 89.3%, 92.9%, 90.5%, 96.2%, and 81.2% (p > 0.05, Dip-Dob vs. Dip-Atro). Conclusion: There was no significant difference in feasibility, safety and diagnostic accuracy between the Dip-Dob and Dip-Atro test. The Dip-Dob test showed more pronounced ability to provoke myocardial ischemia than the Dip-Atro test, expressed as a higher delta WMSI. Both tests confirmed high diagnostic accuracy of pharmacological stress echocardiography in hypertensive patients.